ArticlePloS one2025
Effect of dopamine on TGF-β2 secretion by human retinal pigment epithelial cells and the underlying mechanism.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDopamine is known to play a role in the development of myopia. In this study, we investigated the effect of dopamine (DA) on the secretion of transforming growth factor-β2 (TGF-β2) in human retinal pigment epithelial (RPE) cells. Additionally, we examined the effects of SCH23390 (D1 receptor antagonist) and sulpiride (D2 receptor antagonist) on TGF-β2 levels in ARPE-19 cells to elucidate the underlying mechanism of DA in myopia development.
methodsHuman RPE cells were cultured with or without different concentrations of DA, SCH23390, or sulpiride. Cell proliferation was examined using the CCK-8 assay. Cell migration was assessed by performing a cell scratch (wound healing) assay. The expression of TGF-β2 was evaluated at the mRNA and protein levels by real-time PCR and western blotting, respectively. Furthermore, the secretion of TGF-β2 into the ARPE-19 cell supernatant was quantified using ELISA.
resultsTreatment with 20 μg/mL of DA significantly increased (P < 0.05) the mRNA and protein expression levels of DRD1, DRD2, YAP, and TEAD and decreased TGF-β2 levels compared with that in control group. However, treatment with 24 μg/mL of SCH23390 for 24 h significantly decreased (P < 0.05) DRD1 and TGF-β2 mRNA expression and increased DRD2, YAP, and TEAD mRNA expression in ARPE-19 cells compared with that in the control group. Additionally, the protein expression levels of TGF-β2, YAP, TEAD, and SMAD7 were consistent with the mRNA levels. Notably, treatment with sulpiride (14 μg/mL) increased (P < 0.05) DRD1 and TGF-β2 expression and decreased DRD2, YAP, and TEAD expression in the cells at both the mRNA and protein levels compared with that in the control group.
conclusionsOur findings suggest that dopamine suppresses TGF-β2 secretion in human retinal pigment epithelial cells primarily through activation of D2 receptors, which appears to involve the YAP-TGF-β-Smad signaling pathway. This regulatory mechanism may contribute to the control of scleral remodeling and thus influence the development of myopia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.